Last reviewed · How we verify
TLK286 in combination with docetaxel
At a glance
| Generic name | TLK286 in combination with docetaxel |
|---|---|
| Sponsor | Telik |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TLK286 in combination with docetaxel CI brief — competitive landscape report
- TLK286 in combination with docetaxel updates RSS · CI watch RSS
- Telik portfolio CI